A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer

Trial Profile

A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2009

At a glance

  • Drugs Picoplatin (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2009 Results published in the Journal of Clinical Oncology.
    • 23 Apr 2008 Final results reported at ASLO and ESMO 2008, according to a Poniard Pharmaceutical media release.
    • 23 Apr 2008 Status change from in progress to completed, according to a Poniard Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top